Evoke Pharma Secures U.S. Patent Extension for GIMOTI Until 2038
Evoke Pharma Gains Critical Patent Extension for GIMOTI
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialized pharmaceutical company focused on gastrointestinal (GI) diseases, recently made a significant announcement regarding GIMOTI, its nasal spray formulation for treating diabetic gastroparesis. The U.S. Patent and Trademark Office (USPTO) has officially issued a new patent for GIMOTI, identified as U.S. Patent No. 12,377,064.
New Patent Covers Intranasal Metoclopramide Usage
This newly issued patent covers the application of intranasal metoclopramide for patients suffering from moderate to severe symptoms of gastroparesis. The issuance of this patent is a pivotal milestone for Evoke Pharma, allowing it to solidify its intellectual property surrounding GIMOTI.
Market Exclusivity Extended to Late 2038
An important aspect of this development is the extension of the patent term, now lasting until November 2038, thanks to adjustments made by the USPTO. This extension provides an additional two years of market exclusivity, allowing Evoke to further establish itself in the pharmaceutical landscape. The company intends to include this patent in the FDA's Orange Book, enhancing GIMOTI's protection against generic competition.
CEO's Vision and Commitment
“We are delighted by this issuance of this crucial patent and the extension of exclusivity until November 2038, particularly as we commemorate Gastroparesis Awareness Month,” stated Matt D'Onofrio, CEO of Evoke Pharma. He expressed that this development significantly strengthens their position regarding GIMOTI and underscores the commitment the team has put into its development. The extended exclusivity period will enable the company to better fulfill the needs of patients requiring effective treatment options beyond traditional oral medications.
Focus on Patient Needs
The claims outlined in the patent pertain to treatment methods that involve administering metoclopramide via the nasal route specifically for patients with defined symptom severity associated with gastroparesis. To further enhance its intellectual property, Evoke Pharma plans to pursue additional related claims through a continuation application.
A Commitment to the Gastroparesis Community
Evoke Pharma is also significantly involved in the gastroparesis community and recognizes the importance of raising awareness during Gastroparesis Awareness Month this August. The company is dedicated to improving the quality of life for patients impacted by this often-debilitating condition.
About Evoke Pharma, Inc.
Evoke Pharma is committed to focusing on the development of innovative drug therapies to treat GI disorders. The flagship product, GIMOTI, is designed for adults suffering from acute and recurrent diabetic gastroparesis, effectively addressing the unique challenges presented by this condition.
The Impact of Diabetic Gastroparesis
Diabetic gastroparesis is a complicated GI disorder that slows stomach emptying, affecting millions globally. Patients may experience severe symptoms that complicate their treatment regime, particularly the absorption of orally administered medications. Before GIMOTI's approval, metoclopramide was available only in oral or injectable forms, making GIMOTI the first approved nasal spray treatment for this condition.
Exploring GIMOTI Nasal Spray
The nasally administered GIMOTI offers an important alternative for patients who struggle with traditional medication forms. Not only does GIMOTI aim to alleviate symptoms, but it also provides a critical opportunity to enhance the overall treatment experience for patients.
Conclusion
With the recent patent extension and its ongoing commitment to innovation, Evoke Pharma is poised to solidify its presence in the pharmaceutical market. The company remains dedicated to providing effective solutions for patients dealing with GI disorders, ensuring that the medical community can tackle the challenges of diabetic gastroparesis with innovative treatment options.
Frequently Asked Questions
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide approved for adults suffering from diabetic gastroparesis.
What was the recent patent extension for GIMOTI?
The USPTO extended the patent for GIMOTI until November 2038, granting Evoke Pharma additional market exclusivity.
Why is the patent extension important?
The extension helps Evoke Pharma protect its product from generic competition and allows further investment into research and development.
Who benefits from GIMOTI?
Patients suffering from acute and recurrent diabetic gastroparesis can benefit from GIMOTI as a non-oral treatment option.
How does this development affect Evoke Pharma?
This new patent fortifies Evoke Pharma's position in the market and provides renewed focus on meeting the needs of patients.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
